ReviewThe oncologist2020

The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.

Kyriaki Tzogani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.